News
Pharmaceutical Technology on MSN2d
BeOne Medicines’ BTK degrader gains EMA PRIME designationThe designation was based on the therapy’s novel mechanism and data showing its anti-tumour activity in B-cell malignancies.
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Medicines Agency (EMA) has ...
Kisunla’s active substance is donanemab, a monoclonal antibody that targets and clears amyloid-beta plaques in the brain, a ...
Pharmaceutical Technology on MSN5d
Gilead wins positive European approval opinion for twice-yearly HIV injection"Gilead wins positive European approval opinion for twice-yearly HIV injection" was originally created and published by ...
CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission ...
DPA International on MSN8d
EMA recommends approval of additional Alzheimer's treatmentThe European Medicines Agency (EMA) cleared the way for the use of another drug to treat Alzheimer's disease on Friday.
The European Medicines Agency has recommended authorizing a twice-yearly injectable drug to prevent HIV. LONDON (AP) — The ...
The European Medicines Agency has granted orphan drug designation to narsoplimab for treatment in hematopoietic stem-cell transplant. About Hematopoietic stem cell transplant-associated thrombotic ...
About the author Chris Spivey is the editorial director of Pharmaceutical Technology Europe. Article details Pharmaceutical Technology Europe Volume 36, No. 2 February 2024 Pages 11–14 Citation When ...
On July 2, linvoseltamab-gcpt (Lynozyfic; Regeneron) received an accelerated approval from the FDA in relapsed/refractory ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback